Adventris Analysis: $500K Raised
What is Adventris?
Adventris is a biotechnology company specializing in cancer immunotherapy, developing innovative treatments to enhance the immune system's ability to fight cancer.
Employees
7
Founded
2022
Company Stage
Seed
YC Batch
W23
Product Features & Capabilities
- cancer vaccines targeting specific mutations, first product focuses on lung cancer and KRAS mutation, aims to train the immune system to recognize and eliminate cancer cells, potential for annual vaccinations to prevent cancer deaths, off-the-shelf vaccine for KRAS mutation, annual pan-cancer vaccin
How much Adventris raised
Pre-Seed - $500,000
April 5, 2023Lead Investor: Y Combinator
Who are the founders of Adventris
Investors
- Y Combinator
- Johns Hopkins Technology Ventures
- Refactor Capital
